Thomas P Zonneveld, Sarah E Vermeer, Erik W van Zwet, Adrien E D Groot, Ale Algra, Leo A M Aerden, Kees C L Alblas, Frank de Beer, Paul J A M Brouwers, Koen de Gans, H Maarten A van Gemert, Bart C A M van Ginneken, Gerke S Grooters, Patricia H A Halkes, Tonny A M H G van der Heijden-Montfroy, Korné Jellema, Sonja W de Jong, Harry Lövenich-Ciccarello, Willem D M van der Meulen, Edwin W Peters, Taco C van der Ree, Michel J M Remmers, Edo Richard, Jörgen M P Rovers, Ritu Saxena, Sander M van Schaik, Wouter J Schonewille, Tobien A H C M L Schreuder, Els L L M de Schryver, Wouter J Schuiling, Fianne H Spaander, Julia H van Tuijl, Marieke C Visser, Sanne M Zinkstok, Elles Zock, Diederik W J Dippel, L Jaap Kappelle, Robert J van Oostenbrugge, Yvo B W E M Roos, Frederique H Vermeij, Marieke J H Wermer, H Bart van der Worp, Paul J Nederkoorn, Nyika D Kruyt
BACKGROUND: Intravenous thrombolysis is contraindicated in patients with ischaemic stroke with blood pressure higher than 185/110 mm Hg. Prevailing guidelines recommend to actively lower blood pressure with intravenous antihypertensive agents to allow for thrombolysis; however, there is no robust evidence for this strategy. Because rapid declines in blood pressure can also adversely affect clinical outcomes, several Dutch stroke centres use a conservative strategy that does not involve the reduction of blood pressure...
May 15, 2024: Lancet Neurology